Patent application number | Description | Published |
20080306081 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists - Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders. | 12-11-2008 |
20100035251 | BioMarkers for the Progression of Alzheimer's Disease - The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression. | 02-11-2010 |
20100063029 | USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS - The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said anantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders. | 03-11-2010 |
20100093672 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. | 04-15-2010 |
20100125063 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS - Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders. | 05-20-2010 |
20110212980 | COMBINATIONS FOR THE TREATMENT OF MIGRAINE - The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT | 09-01-2011 |
20120245129 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression. | 09-27-2012 |
20140011884 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression. | 01-09-2014 |
20140235610 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. | 08-21-2014 |